11,302 Shares in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Bought by Arizona State Retirement System

Arizona State Retirement System acquired a new position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,302 shares of the company’s stock, valued at approximately $166,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in shares of Amylyx Pharmaceuticals by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,050,080 shares of the company’s stock worth $92,467,000 after purchasing an additional 124,188 shares during the last quarter. Stonepine Capital Management LLC raised its holdings in shares of Amylyx Pharmaceuticals by 124.4% during the third quarter. Stonepine Capital Management LLC now owns 2,515,868 shares of the company’s stock valued at $46,066,000 after acquiring an additional 1,394,840 shares during the last quarter. Avidity Partners Management LP lifted its position in shares of Amylyx Pharmaceuticals by 94.9% in the third quarter. Avidity Partners Management LP now owns 1,756,940 shares of the company’s stock valued at $32,170,000 after acquiring an additional 855,540 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of Amylyx Pharmaceuticals by 121.3% in the third quarter. Adage Capital Partners GP L.L.C. now owns 1,700,200 shares of the company’s stock worth $31,131,000 after acquiring an additional 932,000 shares during the last quarter. Finally, Emerald Advisers LLC increased its position in shares of Amylyx Pharmaceuticals by 0.8% during the third quarter. Emerald Advisers LLC now owns 838,572 shares of the company’s stock worth $15,354,000 after purchasing an additional 6,764 shares in the last quarter. 95.84% of the stock is owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Trading Up 5.9 %

AMLX opened at $1.98 on Tuesday. The stock’s 50-day moving average price is $7.99 and its 200 day moving average price is $12.72. Amylyx Pharmaceuticals, Inc. has a 12-month low of $1.85 and a 12-month high of $31.21. The firm has a market cap of $134.21 million, a price-to-earnings ratio of 2.83 and a beta of -0.93.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its earnings results on Thursday, February 22nd. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.03. Amylyx Pharmaceuticals had a net margin of 12.94% and a return on equity of 12.39%. The firm had revenue of $108.45 million for the quarter, compared to analysts’ expectations of $106.40 million. During the same quarter last year, the company earned ($0.65) earnings per share. On average, research analysts forecast that Amylyx Pharmaceuticals, Inc. will post -1.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on AMLX. Evercore ISI restated an “in-line” rating on shares of Amylyx Pharmaceuticals in a report on Friday, March 8th. SVB Leerink lowered shares of Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, March 11th. The Goldman Sachs Group reiterated a “neutral” rating on shares of Amylyx Pharmaceuticals in a report on Friday, March 8th. Mizuho cut Amylyx Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, March 18th. Finally, Leerink Partnrs downgraded Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, March 11th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $32.67.

Insider Activity

In other news, insider Gina Mazzariello sold 2,838 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $18.76, for a total transaction of $53,240.88. Following the completion of the sale, the insider now directly owns 46,245 shares in the company, valued at approximately $867,556.20. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CFO James M. Frates sold 1,792 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $18.73, for a total transaction of $33,564.16. Following the sale, the chief financial officer now owns 134,784 shares in the company, valued at $2,524,504.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gina Mazzariello sold 2,838 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $18.76, for a total value of $53,240.88. Following the sale, the insider now owns 46,245 shares of the company’s stock, valued at approximately $867,556.20. The disclosure for this sale can be found here. Insiders have sold a total of 10,305 shares of company stock valued at $193,098 over the last quarter. Corporate insiders own 11.80% of the company’s stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.